2c10534e-5fb7-49b0-8f57-584cb31f3a08
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 68
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANDROGEN_RESPONSE+0.450
- CHOLESTEROL_HOMEOSTASIS+0.440
- FATTY_ACID_METABOLISM+0.420
- INFLAMMATORY_RESPONSE+0.420
- ALLOGRAFT_REJECTION+0.410
- XENOBIOTIC_METABOLISM+0.400
- BILE_ACID_METABOLISM+0.390
- IL6_JAK_STAT3_SIGNALING+0.390
- ADIPOGENESIS+0.380
- INTERFERON_GAMMA_RESPONSE+0.380
Top 10 suppressed
- DNA_REPAIR-0.160
- WNT_BETA_CATENIN_SIGNALING-0.120
- UNFOLDED_PROTEIN_RESPONSE-0.110
- MYC_TARGETS_V2-0.010
- MYOGENESIS-0.010
- MITOTIC_SPINDLE+0.060
- PROTEIN_SECRETION+0.060
- MYC_TARGETS_V1+0.070
- ANGIOGENESIS+0.080
- UV_RESPONSE_DN+0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013498 | — | cohortA1 | 0.874 |
| 2 | 20060039.TNBC | — | C | 0.871 |
| 3 | TCGA-BT-A0YX-01A-11R-A10U-07 | — | — | 0.867 |
| 4 | BS_KEA474HN | low-grade glioma | — | 0.860 |
| 5 | b428d434-2904-4f67-a66f-b7928e2951e3 | — | — | 0.856 |
| 6 | GSM5359441 | — | — | 0.854 |
| 7 | sclcWD9900_S48.txt | — | cohortA1 | 0.851 |
| 8 | TCGA-D8-A1JK-01A-11R-A13Q-07 | — | C | 0.846 |
| 9 | 9afe3e00-86a7-4fdb-a253-0bc8896aafe3 | — | — | 0.843 |
| 10 | GSM5359414 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANDROGEN_RESPONSE | 0.450 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.440 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.420 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.420 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.410 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.400 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.350 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.330 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |